Filing Flows › Comparisons › AURX vs LUCD
Nuo Therapeutics vs Lucid Diagnostics: AURX and LUCD compared
Nuo Therapeutics is the larger company: $1.8M of revenue in its latest quarter (Q2 2026) against $1.5M for Lucid Diagnostics (Q2 2026). Nuo Therapeutics is growing faster (+153% against +27% a year earlier). Nuo Therapeutics is more profitable, with an operating margin of -9.4% against -868.5%.
Where the money goes: AURX and LUCD
Nuo Therapeutics (AURX) · Q2 2026
Nuo Therapeutics, Q2 2026: revenue $1.8M (+153% year over year), operating margin -9.4%, net loss $278K, operating cash flow −$236K. The chart follows the revenue to costs, profit and cash.
Lucid Diagnostics (LUCD) · Q2 2026
Lucid Diagnostics, Q2 2026: revenue $1.5M (+27% year over year), operating margin -868.5%, net loss $11.7M, operating cash flow −$11.3M. The chart follows the revenue to costs, profit and cash.
| Nuo Therapeutics (AURX) | Lucid Diagnostics (LUCD) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.8M | $1.5M |
| Revenue growth, Y/Y | +153% | +27% |
| Operating margin | -9.4% | -868.5% |
| Net earnings | −$278K | −$11.7M |
| Net margin | -15.7% | -792.9% |
| Operating cash flow | −$236K | −$11.3M |
Where the revenue comes from
Nuo Therapeutics
- Product: $1.7M (96%)
- Aurix and Private Label Centrifuge Devices: $72K (4%)
Questions
Which is bigger, Nuo Therapeutics or Lucid Diagnostics?
Nuo Therapeutics is the larger company: $1.8M of revenue in its latest quarter (Q2 2026) against $1.5M for Lucid Diagnostics (Q2 2026).
Is Nuo Therapeutics or Lucid Diagnostics growing faster?
Nuo Therapeutics is growing faster (+153% against +27% a year earlier).
Which is more profitable, Nuo Therapeutics or Lucid Diagnostics?
Nuo Therapeutics is more profitable, with an operating margin of -9.4% against -868.5%.
More: Nuo Therapeutics earnings · how Nuo Therapeutics makes money · Lucid Diagnostics earnings · how Lucid Diagnostics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 14, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.